Tonix Pharmaceuticals Holding Corp., a clinical-stage company that develops first-in-class medicines for common disorders of the central nervous system, including post-traumatic stress disorder, fibromyalgia and episodic tension-type headache, recently announced the presentation of new results of the BESTFIT study, a Phase 2b trial that examined the efficacy of TNX-102 SL in fibromyalgia. The presentation will take place on June 10-13 in Rome, Italy during the 16th Annual European Congress of Rheumatology, hosted by the European League Against Rheumatism (EULAR).
Tonix’s lead product candidate, TNX-102 SLAttribution(cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution (®-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
The poster presentation titled “TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement,” will be presented on the 11th of June from 12:00 p.m. to 1:45 p.m. by R. Michael Gendreau, M.D., Ph.D., Principal, Gendreau Consulting.
The other presentation titled “TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization,” will be presented on the 11th of June from 12:00 p.m. to 1:45 p.m by Seth Lederman, M.D., CEO, Tonix Pharmaceuticals.
The details of the presentations can be found at www.congress.eular.org.
TNX-102 SL is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia and in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 for episodic tension-type headache will begin in the second quarter of 2015.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?